Skip Navigation


Annals of Oncology Advance Access originally published online on April 28, 2005
Annals of Oncology 2005 16(7):1076-1080; doi:10.1093/annonc/mdi215
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/1076    most recent
mdi215v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by West, H. L.
Right arrow Articles by Gandara, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by West, H. L.
Right arrow Articles by Gandara, D. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study

H. L. West1,*, J. J. Crowley2, R. B. Vance3, W. A. Franklin4, R. B. Livingston5, S. R. Dakhil6, J. K. Giguere7, S. E. Rivkin1, M. Kraut8, K. Chansky2 and D. R. Gandara9

1 Swedish Cancer Institute/Puget Sound Oncology Consortium, Seattle, WA; 2 Southwest Oncology Group Statistical Center, Seattle, WA; 3 University of Mississippi Medical Center, Jackson, MS; 4 University of Colorado, Denver, CO; 5 University of Washington/Seattle Cancer Care Alliance, Seattle, WA; 6 Wichita Community Clinical Oncology Program, Wichita, KS; 7 Greenville Community Clinical Oncology Program,Greenville, SC; 8 Providence Cancer Institute,Southfield, MI; 9 University of California, Davis, Sacramento, CA, USA

* Correspondence to: Dr H. L. West, MD, Swedish Cancer Institute/PSOC, 1221 Madison St., 2nd Floor, Seattle, WA 98 104, USA. Tel: +1-206-386-2424; Fax: +1-206-386-2746; Email: howard.west{at}swedish.org

Background:: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC.

Patients and methods:: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1–4) every 21 days for up to six courses.

Results:: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths.

Conclusions:: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

Key words: bronchioloalveolar carcinoma, paclitaxel, prolonged infusion, non-small lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
V. A. Miller, G. J. Riely, M. F. Zakowski, A. R. Li, J. D. Patel, R. T. Heelan, M. G. Kris, A. B. Sandler, D. P. Carbone, A. Tsao, et al.
Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
J. Clin. Oncol., March 20, 2008; 26(9): 1472 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. West, W. A. Franklin, J. McCoy, P. H. Gumerlock, R. Vance, D. H.M. Lau, K. Chansky, J. J. Crowley, and D. R. Gandara
Gefitinib Therapy in Advanced Bronchioloalveolar Carcinoma: Southwest Oncology Group Study S0126
J. Clin. Oncol., April 20, 2006; 24(12): 1807 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Hirsch, M. Varella-Garcia, J. McCoy, H. West, A. C. Xavier, P. Gumerlock, P. A. Bunn Jr, W. A. Franklin, J. Crowley, and D. R. Gandara
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
J. Clin. Oncol., October 1, 2005; 23(28): 6838 - 6845.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.